AZN

AstraZeneca announced FDA approval of Ultomiris (ravulizumab) for reducing proteinuria in adults with primary IgAN at risk of disease progression. This marks the drug's fifth U.S. indication and makes it the first C5 complement inhibitor approved for this use. Ultomiris sales grew 14% to $2.58 billion in H1 2026, though the company faces competition from Calliditas, Novartis, and Travere in the IgAN market.

Summit Therapeutics announced a phase II/III clinical trial (EA2251) evaluating its investigational drug ivonescimab plus chemotherapy as a first-line treatment for advanced biliary tract cancer. The study will compare ivonescimab against Merck's Keytruda and AstraZeneca's Imfinzi, both combined with chemotherapy.

This follows positive results from the HARMONi-GI1 study, which showed ivonescimab demonstrated significant survival benefits over Imfinzi in BTC patients. Summit is expanding ivonescimab development across multiple cancer types while prioritizing lung cancer for near-term U.S. commercialization.

Summit Therapeutics is expanding its investigational drug ivonescimab beyond non-small cell lung cancer into colorectal and bladder cancer indications. The company has initiated phase III trials for metastatic colorectal cancer and phase II/III studies for advanced bladder cancer.

Strategic partnerships with AstraZeneca, GSK, and Arcus Biosciences are evaluating ivonescimab in combination with other cancer therapies, with AstraZeneca committing $2 billion in investment. An FDA decision on ivonescimab for EGFR-mutated NSCLC is expected by November 2026.

VanEck Biotech ETF (BBH) has reached a 52-week high, rising 41.1% from its low, driven by positive Phase 3 results for Amgen and AstraZeneca's Tezspire treatment for eosinophilic esophagitis. The fund shows a positive weighted alpha of 44.96, suggesting potential for continued gains in the near term.

Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities.

Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027.

Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027.

Astrazeneca (AZN) closed at $166.68, up 2.87% in the latest session, outperforming the S&P 500. The pharmaceutical company is trading at a Forward P/E of 17.28, below its industry average of 25.3, suggesting a valuation discount.

However, the stock holds a Zacks Rank #3 (Hold) rating with projected Q3 EPS declining 9.24% year-over-year, though full-year earnings are expected to grow 2.4%. The Medical - Biomedical and Genetics industry ranks in the bottom 38% of all industries.

Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies.

Stock markets declined following a higher-than-expected CPI inflation report. Analysts provided research updates on three major stocks: Mastercard benefits from the shift to electronic payments but faces competitive pricing pressure; AstraZeneca struggles with patent expirations and pipeline setbacks despite strong upcoming drugs; SanDisk outperforms due to AI-driven demand for enterprise SSDs.

Zacks analysts published research on 16 major stocks on October 14, 2026. Mastercard received a Neutral rating despite strong performance, citing competitive pricing pressure and premium valuation concerns.

AstraZeneca faces patent erosion challenges but benefits from strong pipeline drugs and expects $80 billion in revenues by 2030. SanDisk received an Outperform rating, driven by AI inference demand and strong datacenter exposure. Other notable stocks analyzed include Exelon, General Mills, and Halozyme, with mixed outlooks across various sectors.

Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings.

Astrazeneca (AZN) closed at $158.61, up 1.33%, outperforming the S&P 500. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.16 (down 9.24% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 16.71, trading at a discount to its industry average of 22.46.

Summit Therapeutics announced a clinical collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway across multiple solid tumors, starting with a phase III study in first-line triple-negative breast cancer. This partnership builds on AstraZeneca's $2 billion investment in Summit announced the previous week, expanding ivonescimab's development pipeline and creating additional clinical and commercial opportunities.

Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation.

Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

Astrazeneca stock fell 1.17% on September 29, 2026, underperforming the S&P 500's 0.17% decline. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.17 (down 8.82% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.73, trading at a discount to its industry average of 25.2.

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

Healthcare sector is experiencing a significant rebound, with ETFs hovering near 52-week highs driven by double-digit earnings growth expectations, positive clinical trial results, attractive valuations, and expanding GLP-1 adoption. Major pharmaceutical companies reported promising drug-trial outcomes in oncology, obesity, and rare diseases, while M&A activity surged to nearly $284 billion. The sector is benefiting from a rotation out of overcrowded AI/tech trades into defensive growth.

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR.

North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

Alnylam Pharmaceuticals has achieved solid profitability with Q2 2026 net income of $164.5 million and revenue growth of 67% year-over-year, yet its stock has plunged over 40% this year. The decline is attributed to a revenue guidance cut for its drug Amvuttra due to demand normalization and investor concerns about a rival drug's clinical setback. However, Wall Street remains bullish with 19 of 23 analysts recommending a buy, citing the company's strong financials, robust product growth, and promising pipeline.

GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years.

The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV.